研究单位：[1]Eisai Inc.[2]Beijing Friendship Hospital,Capital Medical University Beijing,Beijing,China,100050[3]Xuanwu Hospital Capital Medical University Beijing,Beijing,China,100053[4]Beijing Tiantan Hospital,Capital Medical University Beijing,Beijing,China,100070[5]Sun Yat-Sent Memorial Hospital of Sun Yat-Sen University Guangzhou,Guangdong,China,510120[6]Guangzhou First People's Hospital Guangzhou,Guangdong,China,510180[7]Guangzhou Huiai Hospital Guangzhou,Guangdong,China,510450
研究目的：
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.
